Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07526558 · ClinicalTrials.gov registry record · Phase 2
Mast Cell Treatment in Post-tick Bite Illness (PTBI)
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07526558 is a Phase 2 study that has not yet begun recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 50 participants.
The verdict
NCT07526558, a Phase 2 study, has not yet begun recruiting, sponsored by University of North Carolina, Chapel Hill.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell activation following a documented tick-borne illness (Ehrlichiosis, Rocky Mountain Spotted Fever, Alpha-gal Syndrome).
Interventions
- DRUG Ketotifen
- DRUG Cromolyn Sodium
- DRUG fexofenadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07526558
The ClinicalTrials.gov registry entry for NCT07526558 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketotifen is the first listed.
NCT07526558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07526558 about?
NCT07526558 is a clinical study titled "Mast Cell Treatment in Post-tick Bite Illness (PTBI)". This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell ...
What is the current status of trial NCT07526558?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-04-30. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07526558?
The interventions under investigation include: Ketotifen (DRUG), Cromolyn Sodium (DRUG), fexofenadine (DRUG).
Who is sponsoring clinical trial NCT07526558?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.